The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Says Sjögren’s Patients Have a High Specificity for a Novel Antibody

Study Says Sjögren’s Patients Have a High Specificity for a Novel Antibody

September 17, 2019 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Papa Annur / shutterstock.com

Papa Annur / shutterstock.com

An antibody previously un-recognized in patients with Sjögren’s syndrome may shed new light on the patho­physiology of one of the most troubling and disabling symptoms in many of these patients. Investigators at Johns Hopkins University, Baltimore, found the anti-calponin 3 antibody had a high specificity for Sjögren’s syndrome, particularly among patients with neuropathies.1

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Sjögren’s Complications
  • Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia
  • New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity
Explore This Issue
September 2019
Also By This Author
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis

“There is interest in defining biomarkers of neuropathic pain in patients with Sjögren’s syndrome with neurological complications, and this has traditionally been hampered by the fact that these patients tend to very tenaciously have seronegative disease,” says the study’s lead author, Julius Birnbaum, MD, MHS, assistant professor of medicine and neurology, and director of the Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center at the Johns Hopkins University School of Medicine in Baltimore. “That is why we’re excited that we found a trend toward one unique specificity,” he says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

New Target for Antibody Specificity

Dr. Birnbaum and colleagues pursued a novel paradigm by immunoblotting patient serum against lysates from rat dorsal root ganglia (DRG). Dr. Birnbaum explained that antibodies against the DRG are relevant in patients with Sjögren’s syndrome because the DRG have been implicated in various autoimmune neurological disorders. They identified one novel antibody that was specific for the DRG: anti-calponin 3.

“Anti-calponin 3 was known to be an actin-binding protein that has been defined in cells with muscle tissue as well as the central nervous system, but has not been previously recognized to be expressed in the peripheral nervous system,” Dr. Birnbaum says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Of 209 patients with Sjögren’s syndrome in the study, the researchers detected anti-calponin 3 antibodies in 23 (11%). When looking at patients with other types of autoimmune rheumatic diseases, they found the antibodies in 12 (8.7%) of 138 patients with systemic lupus erythematosus, in seven (5.1%) of 138 patients with myositis, in three (6.8%) of 44 patients with multiple sclerosis and one (2.2%) of 46 healthy controls.

Dr. Birnbaum‘The potential pathogenesis of underlying neuropathies in Sjögren’s syndrome might be somewhat indirect & targeted against perineuronal satellite cells & not the underlying DRG neuron.’—Dr. Birnbaum

Specificity in Patients with Neurologic Disease

To look for the frequency of anti-calponin 3 antibodies in patients with neuro­logic disease, the investigators divided the patients with Sjögren’s syndrome into three subgroups: those with no evidence of neuropathies (n=99), those with underlying neuropathies (n=39) and those with neuropathic-type pain without neuropathies (n=71). The patients with underlying neuropathy had a higher frequency of anti-calponin 3 antibodies (18%) when compared with healthy controls (2.2%). This finding, Dr. Birnbaum says, shows that anti-calponin 3 is enriched in Sjögren’s syndrome patients with neuropathies.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

But Dr. Birnbaum says the most interesting finding was that the antibodies did not target the actual DRG neuron, but instead targeted the perineuronal satellite cells, which are the non-neuronal cells within the DRG.

Pages: 1 2 | Single Page

Filed Under: Conditions, Research Reviews, Systemic Inflammatory Syndromes Tagged With: anti-calponin 3, Biomarkers, Sjögren's syndromeIssue: September 2019

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Sjögren’s Complications
  • Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia
  • New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity
  • The Value of Repeat Antibody Testing in Lupus Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.